Trial · NCT00984282
Participant flow22
How many started, completed or left each group, period by period.
1 to 20 of 22
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double Blind Treatment | STARTED | DB Sorafenib First, Then Option of OL Sorafenib Treatment | 207 | |
| Double Blind Treatment | STARTED | DB Placebo First, Then Option of OL Sorafenib Treatment | 210 | |
| Double Blind Treatment | Received Treatment | DB Sorafenib First, Then Option of OL Sorafenib Treatment | 207 | |
| Double Blind Treatment | Received Treatment | DB Placebo First, Then Option of OL Sorafenib Treatment | 209 | |
| Double Blind Treatment | COMPLETED | DB Sorafenib First, Then Option of OL Sorafenib Treatment | 103 | |
| Double Blind Treatment | COMPLETED | DB Placebo First, Then Option of OL Sorafenib Treatment | 172 | |
| Double Blind Treatment | NOT COMPLETED | DB Sorafenib First, Then Option of OL Sorafenib Treatment | 104 | |
| Double Blind Treatment | NOT COMPLETED | DB Placebo First, Then Option of OL Sorafenib Treatment | 38 | |
| Open-label Treatment | STARTED | DB Sorafenib First, Then Option of OL Sorafenib Treatment | 86 | |
| Open-label Treatment | STARTED | DB Placebo First, Then Option of OL Sorafenib Treatment | 161 | |
| Open-label Treatment | Received Treatment | DB Sorafenib First, Then Option of OL Sorafenib Treatment | 86 | |
| Open-label Treatment | Received Treatment | DB Placebo First, Then Option of OL Sorafenib Treatment | 161 | |
| Open-label Treatment | COMPLETED | DB Sorafenib First, Then Option of OL Sorafenib Treatment | 0 | |
| Open-label Treatment | COMPLETED | DB Placebo First, Then Option of OL Sorafenib Treatment | 0 | |
| Open-label Treatment | NOT COMPLETED | DB Sorafenib First, Then Option of OL Sorafenib Treatment | 86 | |
| Open-label Treatment | NOT COMPLETED | DB Placebo First, Then Option of OL Sorafenib Treatment | 161 | |
| Long Term Follow-up | STARTED | DB Sorafenib First, Then Option of OL Sorafenib Treatment | 72 | |
| Long Term Follow-up | STARTED | DB Placebo First, Then Option of OL Sorafenib Treatment | 124 | |
| Long Term Follow-up | COMPLETED | DB Sorafenib First, Then Option of OL Sorafenib Treatment | 3 | |
| Long Term Follow-up | COMPLETED | DB Placebo First, Then Option of OL Sorafenib Treatment | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00984282/flow